FDA ApprovedWeight LossMetabolic

Tirzepatide

Mounjaro

Dual GIP/GLP-1 Receptor Agonist | Weight Loss & Diabetes

Half-life

~5 days (120 hours)

Chain length

39 amino acids

Reference frequency

Once weekly (same day each week)

Research overview

DoseGear research brief

Revolutionary dual receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Demonstrates efficacy superior to single-mechanism alternatives with 15-22% body weight reduction in clinical trials. The first-in-class dual GIP/GLP-1 agonist provides enhanced metabolic benefits compared to GLP-1-only medications.

Mechanism of action

Dual agonist targeting both GIP and GLP-1 receptors, producing glucose-dependent insulin stimulation, delayed gastric emptying, glucagon suppression, and central satiety signaling via hypothalamic pathways.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Engineered dual GIP/GLP-1-receptor agonist medicine.

What it is researched for

Type 2 diabetes, obesity, and related outcome research through combined GIP- and GLP-1-receptor activation.

Research observation window

Cited studies include 72-week weight trials, about three years of diabetes-prevention follow-up, and median 104-week heart-failure follow-up.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research context	Amount	Frequency	Route
Weight loss initiation	2.5mg	Once weekly x 4 weeks	SubQ injection
Weight loss progression	5mg	Once weekly	SubQ injection
Weight loss optimization	7.5-10mg	Once weekly	SubQ injection
Maximum weight loss	12.5-15mg	Once weekly	SubQ injection
Diabetes management (mild)	5-7.5mg	Once weekly	SubQ injection
Diabetes management (severe)	10-15mg	Once weekly	SubQ injection

Reference cycle

Ongoing therapy as prescribed

Reference storage

Pen: 2-8°C before first use, room temp up to 21 days after; Compounded: 2-8°C

Safety context

Reported side effects

Nausea (mild to moderate, first 2-4 weeks)
Appetite reduction
Possible fatigue during adaptation
Diarrhea or constipation
Reduced food cravings

Contraindications & cautions

Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pregnancy or breastfeeding
History of pancreatitis

Scientific references

01
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Scientific citationTirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine (2022).
02
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
Scientific citationTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine (2021).
03
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
Scientific citationTirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). The Lancet (2023).
04
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT)
Scientific citationCardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT). New England Journal of Medicine (2025).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Longevity